Skip to main content
    I

    Ideaya Biosciences Inc (IDYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $33.85
    -0.01 (-0.03%)

    Market Cap: $3.31B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(16/29)
    Avg Surprise
    -3.79%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.16
    Range$-1.42 - $-0.84
    12 analysts
    EPS Revisions
    1
    0
    7d
    1
    11
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.06-9.8%
    60d ago$-1.04-12.0%
    30d ago$-1.17+0.8%
    7d ago$-1.17+0.8%
    Current$-1.16
    Revenue Consensus
    $7M
    Range$0 - $35M
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.39
    Range$-2.01 - $-0.83
    12 analysts
    Revenue Consensus
    $22M
    Range$-3921320 - $66M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.39---
    Sep 26EST
    		-$-1.16---
    Jun 26
    Reported Aug 4
    		$-1.22$-1.18-3.39%Miss-38.6%
    Mar 26
    Reported May 5
    		$-1.11$-0.98-13.27%Miss-35.4%
    Dec 25
    Reported Feb 17
    		$-0.94$-0.95+1.05%Beat+36.9%
    Sep 25
    Reported Nov 4
    		$1.33$-0.55+341.82%Beat+321.7%
    Jun 25
    Reported Aug 5
    		$-0.88$-0.79-11.39%Miss-29.4%
    Mar 25
    Reported May 6
    		$-0.82$-0.69-18.84%Miss-54.7%
    Dec 24
    Reported Feb 13
    		$-1.49$-0.62-139.36%Miss-186.5%
    Sep 24
    Reported Nov 4
    		$-0.60$-0.63+4.76%Beat-30.4%
    Jun 24
    Reported Aug 6
    		$-0.68$-0.53-28.30%Miss-36.0%
    Mar 24
    Reported May 7
    		$-0.53$-0.50-6.00%Miss-8.2%
    Dec 23
    Reported Feb 20
    		$-0.52$-0.46-13.04%Miss-4.0%
    Sep 23
    Reported Nov 7
    		$-0.46$-0.50+8.00%Beat-1250.0%
    Jun 23
    Reported Aug 10
    		$-0.50$-0.55+9.09%Beat+12.3%
    Mar 23
    Reported May 9
    		$-0.49$-0.54+9.26%Beat-36.1%
    Dec 22
    Reported Mar 7
    		$-0.50$-0.56+10.71%Beat-6.4%
    Sep 22
    Reported Nov 8
    		$0.04N/A+106.45%Beat+112.9%
    Jun 22
    Reported Aug 15
    		$-0.57$-0.51-11.76%Miss-72.7%
    Mar 22
    Reported May 10
    		$-0.36$-0.42+14.29%Beat-28.6%
    Dec 21
    Reported Mar 15
    		$-0.47$-0.31-51.61%Miss-161.1%
    Sep 21
    Reported Nov 15
    		$-0.31$-0.31+0.00%Beat-82.4%
    Jun 21
    Reported Aug 10
    		$-0.33$-0.08-312.50%Miss+44.1%
    Mar 21
    Reported May 10
    		$-0.28$-0.36+22.22%Beat+52.5%
    Dec 20
    Reported Mar 23
    		$-0.18$-0.30+40.00%Beat+66.0%
    Sep 20
    Reported Nov 12
    		$-0.17N/A-115.04%Miss+68.5%
    Jun 20
    Reported Aug 12
    		$-0.59$-0.62+4.84%Beat-13.5%
    Mar 20
    Reported May 12
    		$-0.59$-0.58-1.72%Miss+66.5%
    Dec 19
    Reported Mar 24
    		$-0.53$-0.57+7.02%Beat-
    Sep 19
    Reported Nov 13
    		$-0.54$-0.66+18.18%Beat-
    Jun 19
    Reported Aug 12
    		$-0.52$-0.64+18.75%Beat-
    Mar 19
    Reported May 24
    		$-1.76N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-17.45EV/EBITDAN/A
    Price/FCF-27.37xFCF Yield-3.65%
    Profitability
    Profit Margin-74.80%Operating Margin-1381.00%
    ROE-16.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio10.45xQuick Ratio10.45x
    Trading Statistics
    Beta-0.04Avg Volume932.31K
    52-Week High$42.6852-Week Low$26.81

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$35.85
    SMA 20$36.93
    SMA 50$37.96
    SMA 200$34.12
    EMA 10$35.52
    EMA 20$36.48
    EMA 50$37.01
    EMA 200$34.01

    MACD

    Line: -1.01Signal: -0.61Hist: -0.39

    ADX

    ADX: 16.7+DI: 14.3-DI: 29.0

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$38.62

    Bollinger Bands

    Upper Band$40.17
    Lower Band$33.70
    %B Position1753%(Upper)
    Band Width0.02

    RSI (14-Day)

    Neutral
    30.5

    Momentum Oscillators

    Stoch %K2.8
    Stoch %D8.2
    Williams %R-96.0
    ROC (10d)-10.5%
    Momentum-3.96
    CCI (20d)-160.9
    MFI (14d)38.8

    Volatility Measures

    ATR (14d)$1.39(4.1%)
    StdDev (20d)1.62
    Hist Vol37.1%(Moderate)

    Volume Flow

    VWAP$34.05
    OBV42.4M
    AD Line-9.3M
    CMF (20d)-0.260

    Volume Metrics

    Avg Vol (20d)955.7K
    Vol Ratio1.4x
    VWMA (20d)$36.97

    Pivot Points

    R3$35.81
    R2$35.33
    R1$34.59
    Pivot Point$34.11
    S1$33.37
    S2$32.89
    S3$32.15

    Advanced Oscillators

    TSI-22.84
    Ultimate Osc32.7
    KST-65.73

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.86M$6.56M$10.88M$207.83M$0$0$7.00M$0$0$0$3.92M$8.04M
    Cost of Revenue$0$0$1.20M$0$0$0$643,000$0$0$0$1.02M$0
    Gross Profit$8.86M$6.56M$10.88M$207.83M$0$0$7.00M$0$0$0$3.92M$8.04M
    Operating Expenses$131.15M$115.10M$105.45M$99.38M$88.81M$84.39M$151.14M$66.89M$64.93M$51.02M$45.84M$41.56M
    R&D$108.69M$95.73M$86.60M$82.99M$74.23M$70.89M$140.18M$57.15M$54.53M$42.80M$38.77M$33.70M
    SG&A$22.46M$19.38M$18.85M$16.39M$14.58M$13.50M$10.96M$9.74M$10.39M$8.21M$7.07M$7.86M
    Operating Income$-122,291,000$-108,544,000$-94,570,000$108.45M$-88,806,000$-84,389,000$-144,138,000$-66,893,000$-64,927,000$-51,017,000$-41,915,000$-33,526,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-122,291,000$-98,539,000$-61,166,000$108.45M$-88,806,000$-72,178,000$-91,640,000$-66,893,000$-64,927,000$-51,017,000$-23,086,000$-33,526,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-112,452,000$-98,539,000$-83,273,000$119.24M$-77,491,000$-72,178,000$-130,312,000$-51,821,000$-52,772,000$-39,572,000$-33,955,000$-27,440,000
    EBITDA$-122,188,000$-98,607,000$-94,897,000$107.50M$-90,265,000$-74,823,000$-148,411,000$-71,244,000$-70,470,000$-56,249,000$-44,767,000$-36,066,000
    EBIT$-122,291,000$-98,539,000$-94,570,000$108.45M$-88,806,000$-72,178,000$-144,138,000$-66,893,000$-64,927,000$-51,017,000$-41,915,000$-33,526,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IDYA

    News

    William Blair initiates Ideaya Biosciences stock with outperform rating

    William Blair has initiated coverage on Ideaya Biosciences (NASDAQ: IDYA) with an outperform rating, citing the potential approval of darovasertib for metastatic uveal melanoma in the first half of 2027. The drug showed...

    Investing.com•10/16/26•Bullish

    Stifel sets USD 48.00 target for IDEAYA Biosciences stock

    Stifel has set a USD 48.00 price target for IDEAYA Biosciences (NASDAQ: IDYA) with a "Buy" rating, which is 42.35% higher than its current Nasdaq quote. The biotechnology company is scheduled to report its third-quarter...

    ad-hoc-news.de•10/15/26•Bullish

    Stifel initiates Ideaya Biosciences stock with buy rating By Investing.com

    Stifel has initiated coverage on Ideaya Biosciences (NASDAQ: IDYA) with a buy rating and a price target of $48.00...

    Investing.com Canada•10/14/26•Bullish

    IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma (IDYA:NASDAQ)

    Stifel has resumed coverage of IDEAYA Biosciences (IDYA) with a Buy rating, citing the potential for the company's darovasertib and crizotinib combination to become the standard of care for first-line metastatic uveal...

    Seeking Alpha•10/14/26•Bullish

    Trading the Move, Not the Narrative: (IDYA) Edition

    This article provides an AI-generated analysis for Ideaya Biosciences Inc. (NASDAQ: IDYA), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details specific institutional trading...

    Stock Traders Daily•10/12/26•Somewhat-Bearish

    IDYA Valuation and Fair Value

    P/E
    -17.4x
    Forward P/E
    4.7x
    P/FCF
    -27.4x
    P/B
    2.6x
    See GNG's fair value

    IDYA Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -1381.0%
    Net margin
    -74.8%
    ROE
    -16.2%
    FCF margin
    -48.6%
    FCF yield
    -3.7%

    IDYA Competitors

    CompanyTicker
    Arcutis Biotherapeutics IncARQT
    Warby Parker IncWRBY
    Xenon Pharmaceuticals IncXENE
    Celcuity LLCCELC
    Tarsus Pharmaceuticals IncTARS
    Enliven Therapeutics Inc.ELVN
    CareDx IncCDNA
    Denali Therapeutics IncDNLI

    Sector: Healthcare

    IDYA Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    3
    Buy
    10
    Hold
    1
    Sell
    0
    Strong Sell
    0

    IDYA Bull Case vs Bear Case

    Bull case

    • IDYA grew quarterly revenue 55.4% year over year.
    • 92.9% of IDYA's analyst ratings are Buy or Strong Buy.

    Bear case

    • IDYA has a -74.8% net profit margin.
    • IDYA beat EPS estimates in 37.5% of its last 8 reported quarters.

    IDYA Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    20.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.16
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 11 down

    Frequently Asked Questions About IDYA

    Does IDYA pay dividends?

    Ideaya Biosciences Inc (IDYA) does not currently pay a regular dividend.

    What is IDYA's market cap?

    Ideaya Biosciences Inc (IDYA) has a market capitalization of $3.31B with a current stock price of $33.85.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In